SCHEMBL9537347

SCHEMBL9537347

Cc1cc(-c2ccccc2)n2nc(N)nc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 1.00
ALDH1A1 P00352 8/20 0.78
HPGD P15428 7/20 0.78
SMN1; SMN2 Q16637 4/20 0.78
HSD17B10 Q99714 3/20 0.74
MAPK1 P28482 3/20 0.74
HTT P42858 2/20 0.70
MAPT P10636 4/20 0.57
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CKS1B P61024 2/20 0.52
SKP2 Q13309 2/20 0.52
PDE10A Q9Y233 1/20 0.51
NUDT1 P36639 1/20 0.50
GLA P06280 1/20 0.48
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18499244 0.85 KDM4E (0.74) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL17125465 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL9534978 0.81 KDM4E (0.68) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL9537071 0.81 KDM4E (0.68) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL9534983 0.81 KDM4E (0.68) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL9534494 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL9535280 0.78 KDM4E (0.63) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL9537624 0.77 KDM4E (0.62) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL9538826 0.75 KDM4E (0.71) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL10558826 0.74 RECQL (0.61) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398749-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2019-09-03 US disclosed
US-10398680-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2019-09-03 US disclosed
US-20190240195-A1 METHODS OF TREATING MUSCULAR DYSTROPHY Board of Regents of the Nevada System of Higher Education, on behalf of the Univ of Nevada, Reno (US) 2019-08-08 US disclosed
US-10272069-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2019-04-30 US disclosed
US-10206903-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2019-02-19 US disclosed
US-10028992-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2018-07-24 US disclosed
US-10028992-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2018-07-24 US disclosed
EP-2892525-B1 METHODS OF TREATING MUSCULAR DYSTROPHY UNIV NEVADA RENO (US) 2018-06-13 EP disclosed
US-9980943-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEMS OF HIGHER EDUCATION ON BEHALF OF THE NEVADA, RENO (US) 2018-05-29 US disclosed
US-9980943-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEMS OF HIGHER EDUCATION ON BEHALF OF THE NEVADA, RENO (US) 2018-05-29 US disclosed
US-20150290276-A1 METHODS OF TREATING MUSCULAR DYSTROPHY BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY 2015-10-15 US disclosed
US-20150290276-A1 METHODS OF TREATING MUSCULAR DYSTROPHY BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY 2015-10-15 US disclosed
WO-2014144606-A2 METHODS OF TREATING MUSCULAR DYSTROPHY BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2014-09-18 WO disclosed
WO-2014040077-A1 METHODS OF TREATING MUSCULAR DYSTROPHY BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSISITY OF NEVADA, RENO (US) 2014-03-13 WO disclosed
US-20140072536-A1 METHODS OF TREATING MUSCULAR DYSTROPHY BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) 2014-03-13 US disclosed
US-20140072536-A1 METHODS OF TREATING MUSCULAR DYSTROPHY BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) 2014-03-13 US disclosed
EP-0353902-B1 SUBSTITUTED PHENYLTRIAZOLOPYRIMIDINE HERBICIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1993-05-05 EP disclosed
US-5127936-A Substituted phenyltriazolopyrimidine herbicides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-07-07 US disclosed
WO-1990012012-A1 SUBSTITUTED PHENYLTRIAZOLOPYRIMIDINE HERBICIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-10-18 WO disclosed
EP-0353902-A1 Substituted phenyltriazolopyrimidine herbicides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150290276-A1 METHODS OF TREATING MUSCULAR DYSTROPHY ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885ALDH1A1 342/4885HPGD 1684/4885
US-10272069-B2 Methods of treating muscular dystrophy ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885ALDH1A1 342/4885HPGD 1684/4885
US-10028992-B2 Methods of treating muscular dystrophy ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885ALDH1A1 342/4885HPGD 1684/4885
US-10398680-B2 Methods of treating muscular dystrophy ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885ALDH1A1 342/4885HPGD 1684/4885
US-10398749-B2 Methods of treating muscular dystrophy ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885ALDH1A1 342/4885HPGD 1684/4885
US-20190240195-A1 METHODS OF TREATING MUSCULAR DYSTROPHY ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885ALDH1A1 342/4885HPGD 1684/4885
US-10206903-B2 Methods of treating muscular dystrophy ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885ALDH1A1 342/4885HPGD 1684/4885
US-20140072536-A1 METHODS OF TREATING MUSCULAR DYSTROPHY ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885ALDH1A1 342/4885HPGD 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.